Want to see CGEM full AI Analyst Report?
Velinotamig Specified Dose On Specified Days.
Warm Autoimmune Hemolytic Anemia (Waiha), Immune Thrombocytopenia (Itp)
Phase I/II
Not Yet Recruiting
A Phase 1b/2a Study of Velinotamig in Adults With Relapsed/Refractory ITP and wAIHA
Jul 28, 2026
―
Pembrolizumab, Cln-617, Keytruda
Advanced Solid Tumor
Phase I
Terminated
CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Aug 31, 2023
―
Cln-081
Non Small Cell Lung Cancer, Egfr Exon 20 Mutation
Phase I/II
Active Not Recruiting
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Jul 23, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Cullinan Management (CGEM) have in its pipeline
CGEM is currently developing the following drugs: Velinotamig Specified Dose On Specified Days., Cln-978, Pembrolizumab, Cln-617, Keytruda. These drug candidates are in various stages of clinical development as the company works toward FDA approval.